Key Highlights
- Price $21.12 · Market cap in the multi‑billion range · Surges 8.9% after promising trial data · Next catalyst: Phase 3 pancreatic trial next year
- Shares rose 8.9% to close at $19.50 following a Phase 1 trial that cut pancreatic tumors by 57%
- EPS missed consensus estimates, highlighting a wider loss than analysts projected
- Jeopardies lifted its target price to $24, a 14% increase, while HC Wainwright kept a $20 target
Erasca Inc. (NASDAQ: ERAS) witnessed its share price jump 8.9% to $19.50 after a Phase 1 investigation of its ERAS‑0015 candidate reported a 57% shrinkage of pancreatic tumors. The company posted a loss per share that fell short of analyst expectations for the most recent quarter, underscoring a broader gap between forecasts and results. The compelling data prompted Jefferies to raise its price target by 14% to $24, while HC Wainwright maintained its $20 target and continued its buy stance.
Ongoing interest from hedge funds adds further momentum as the stock advances.
By the Numbers
The earnings release highlighted a per‑share loss that missed consensus expectations, widening the divergence between market forecasts and actual performance. Erasca’s market capitalization remains in the multi‑billion‑dollar range, reflecting a strong year‑to‑date trajectory and notable recent gains. The stock currently trades around $21.12, with recent trading activity showing modest fluctuations after the headline‑making trial announcement.
Segment Detail
The Phase 1 trial enrolled a small cohort of patients with pancreatic cancer, and ERAS‑0015 achieved a 57% reduction in measurable tumor burden. Most participants remained on therapy beyond the eight‑week mark, suggesting a tolerable safety profile alongside efficacy. The company intends to commence a Phase 3 pancreatic study in the coming year, expanding the enrollment pool to validate these early signals.
In addition, a lung‑cancer program is slated for activation later in the decade, broadening the pipeline beyond the current focus. Successful outcomes in either indication could solidify the company’s therapeutic platform and support the premium valuation applied by investors.
Guidance
Analysts at Jefferies elevated their price target by 14% to $24, reflecting confidence in the upcoming Phase 3 data and the broader pipeline. HC Wainwright upheld its buy recommendation with a $20 target, indicating belief that the current share price still undervalues the firm’s growth prospects. The prevailing consensus suggests that positive Phase 3 results will serve as the primary catalyst for further upside, while any setback could prompt a rapid reassessment of the stock’s premium.
Market Reaction
Following the initial rally, ERAS shares experienced a modest pull‑back in pre‑market trading, reflecting a slight retreat after the headline‑grabbing trial news. This movement occurs amid strong year‑to‑date performance, yet the market remains attentive to the timing of the Phase 3 readout. Continued hedge‑fund participation provides a supportive base that may mitigate short‑term volatility.
Investors will be monitoring forthcoming trial milestones closely, as these events are likely to determine whether the recent price gains can be sustained.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...